LYG
MCID: LYM051
MIFTS: 45

Lymphomatoid Granulomatosis (LYG)

Categories: Blood diseases, Immune diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Lymphomatoid Granulomatosis

MalaCards integrated aliases for Lymphomatoid Granulomatosis:

Name: Lymphomatoid Granulomatosis 52 58 54 37 71
Lyg 58

Characteristics:

Orphanet epidemiological data:

58
lymphomatoid granulomatosis
Inheritance: Not applicable; Age of onset: Adult;

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

MESH via Orphanet 44 D008230
ICD10 via Orphanet 33 C83.8
UMLS via Orphanet 72 C0024307
Orphanet 58 ORPHA86869
UMLS 71 C0024307

Summaries for Lymphomatoid Granulomatosis

NIH Rare Diseases : 52 Lymphomatoid granulomatosis is a rare disorder characterized by an overproduction of white blood cells known as B lymphocytes . These B cells can build up in the tissues of the body, causing damage to the blood vessels. In many cases of lymphomatoid granulomatosis, the abnormal B cells contain the Epstein-Barr virus . The disease is more common in men, usually after the fifth decade of life. Lymphomatoid granulomatosis most commonly affects the lungs, though other areas of the body may also be affected. Signs and symptoms vary but can include cough, shortness of breath, tightness of the chest, fever, weight loss, and fatigue. Skin lesions and central nervous system changes such as headaches, seizures , and ataxia may also be seen. Rarely, the disorder can affect the kidneys or liver. The cause of the disorder is not well understood, though a combination of genetic and immune factors are thought to play a part. Treatment depends on the extent of the disease but may include interferon alfa-2b and combination chemotherapy with rituximab . Occasionally, the disorder resolves on its own without treatment. There has been some debate as to whether lymphomatoid granulomatosis should be viewed as a as a B-cell lymphoma or a lymphoproliferative disease or whether it should be viewed merely as a condition that can develop into a B-cell lymphoma. The prognosis is variable, though lymphomatoid granulomatosis can progress and become fatal in some cases.

MalaCards based summary : Lymphomatoid Granulomatosis, also known as lyg, is related to splenomegaly and acquired immunodeficiency syndrome, and has symptoms including fever and malaise. An important gene associated with Lymphomatoid Granulomatosis is IFNA2 (Interferon Alpha 2), and among its related pathways/superpathways are Toll-like Receptor Signaling Pathway and Allograft rejection. The drugs Clavulanate and Amoxicillin have been mentioned in the context of this disorder. Affiliated tissues include b cells, lung and t cells.

Wikipedia : 74 Lymphomatoid granulomatosis (LYG or LG) is a very rare lymphoproliferative disorder first characterized... more...

Related Diseases for Lymphomatoid Granulomatosis

Diseases related to Lymphomatoid Granulomatosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 258)
# Related Disease Score Top Affiliating Genes
1 splenomegaly 30.2 IFNA2 IFNA1
2 acquired immunodeficiency syndrome 30.1 IFNA2 IFNA1
3 lethal midline granuloma 30.1 TIA1 GZMB
4 panniculitis 29.8 TIA1 GZMB
5 peripheral t-cell lymphoma 29.7 TIA1 GZMB
6 lymphomatoid papulosis 29.6 TIA1 GZMB
7 angioimmunoblastic t-cell lymphoma 29.5 TIA1 GZMB
8 lymphoma, hodgkin, classic 29.5 TIA1 GZMB
9 viral infectious disease 29.3 IFNA2 IFNA1 GZMB
10 mycosis fungoides 27.8 TIA1 IFNA2 IFNA1 GZMB CXCL9
11 lymphoproliferative syndrome 1 11.6
12 lymphoproliferative syndrome, x-linked, 1 11.5
13 lymphoproliferative syndrome 10.9
14 lymphoma 10.7
15 b-cell lymphoma 10.7
16 vasculitis 10.6
17 diffuse large b-cell lymphoma 10.5
18 sarcoidosis 1 10.4
19 lung disease 10.4
20 polymorphic reticulosis 10.4
21 immune deficiency disease 10.4
22 exanthem 10.4
23 respiratory failure 10.4
24 granulomatosis with polyangiitis 10.3
25 rheumatoid arthritis 10.2
26 human immunodeficiency virus type 1 10.2
27 leukemia, acute lymphoblastic 10.2
28 pancytopenia 10.2
29 neuropathy 10.2
30 wiskott-aldrich syndrome 10.2
31 agammaglobulinemia 10.2
32 pneumonia 10.2
33 retroperitoneal fibrosis 10.2
34 leukemia, chronic lymphocytic 10.1
35 systemic lupus erythematosus 10.1
36 leprosy 3 10.1
37 leukemia, acute myeloid 10.1
38 hemophagocytic lymphohistiocytosis 10.1
39 aphasia 10.1
40 crohn's colitis 10.1
41 childhood acute lymphocytic leukemia 10.1
42 pleurisy 10.1
43 hemiplegia 10.1
44 leukemia 10.1
45 richter's syndrome 10.1
46 histoplasmosis 10.1
47 dermatitis 10.1
48 glomerulonephritis 10.1
49 interstitial lung disease 10.1
50 central nervous system disease 10.1

Graphical network of the top 20 diseases related to Lymphomatoid Granulomatosis:



Diseases related to Lymphomatoid Granulomatosis

Symptoms & Phenotypes for Lymphomatoid Granulomatosis

UMLS symptoms related to Lymphomatoid Granulomatosis:


fever, malaise

Drugs & Therapeutics for Lymphomatoid Granulomatosis

Drugs for Lymphomatoid Granulomatosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 196)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Clavulanate Approved, Vet_approved Phase 3 58001-44-8 5280980
2
Amoxicillin Approved, Vet_approved Phase 3 26787-78-0 33613
3
Ciprofloxacin Approved, Investigational Phase 3 85721-33-1 2764
4 Orange Approved Phase 3
5
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
6
Iron Approved, Experimental Phase 3 15438-31-0, 7439-89-6 27284 23925
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
9
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
10
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
11 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
12 Amoxicillin-Potassium Clavulanate Combination Phase 3
13 beta-Lactamase Inhibitors Phase 3
14 Excitatory Amino Acid Antagonists Phase 3
15 Anesthetics, Dissociative Phase 3
16 Liver Extracts Phase 3
17 Cola Phase 3
18 Analgesics Phase 3
19 Narcotics Phase 3
20 Analgesics, Opioid Phase 3
21 Anesthetics Phase 3
22 Anesthetics, General Phase 3
23 Anesthetics, Intravenous Phase 3
24 Hematinics Phase 3
25 ferric gluconate Phase 3
26 Iron Supplement Phase 3
27
Bortezomib Approved, Investigational Phase 1, Phase 2 179324-69-7 387447 93860
28
Doxorubicin Approved, Investigational Phase 1, Phase 2 23214-92-8 31703
29
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
30
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
31
Arsenic trioxide Approved, Investigational Phase 2 1327-53-3 518740
32
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
33
Melphalan Approved Phase 2 148-82-3 460612 4053
34
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
35
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
36
Sorafenib Approved, Investigational Phase 1, Phase 2 284461-73-0 216239 406563
37
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
38
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
39
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
40
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
41 Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
42
Promethazine Approved, Investigational Phase 2 60-87-7 4927
43
Acetaminophen Approved Phase 2 103-90-2 1983
44
Diphenhydramine Approved, Investigational Phase 2 58-73-1, 147-24-0 3100
45
Caspofungin Approved Phase 2 162808-62-0, 179463-17-3 2826718 468682
46
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
47
Benzyl alcohol Approved Phase 2 100-51-6 244
48
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
49
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
50
nivolumab Approved Phase 2 946414-94-4

Interventional clinical trials:

(show top 50) (show all 177)
# Name Status NCT ID Phase Drugs
1 A Prospective Randomised Phase III Trial of Early Hospital Discharge Versus Standard Inpatient Management of Cancer Patients With Low-Risk Febrile Neutropenia Receiving Oral Antibiotics. Oral Antibiotics for Neutropenic Sepsis Giving Early Hospital Discharge [ORANGE] Unknown status NCT00445497 Phase 3 amoxicillin-clavulanate potassium;ciprofloxacin
2 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
3 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
4 Glutamic Acid to Decrease Vincristine Toxicity in Children With Cancer Completed NCT00369564 Phase 3 glutamic acid
5 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
6 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
7 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
8 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
9 Allograft of Hematopoietic Stem Cells With Reduced-intensity Conditioning From a HLA-haploidentical Family Donor: Phase II Study of Combined Immunosuppression Before and After Transplantation Unknown status NCT00740467 Phase 2 busulfan;cyclophosphamide;cyclosporine;fludarabine phosphate;mycophenolate mofetil
10 Clinical Research of Gene Therapy for Refractory B-Cell Non-Hodgkin Lymphoma Using Autologous T Cells Expressing a Chimeric Antigen Receptor Specific to the CD19 Antigen Unknown status NCT02134262 Phase 1, Phase 2 Cyclophosphamide or Bendamustine
11 Impact of Intervention With Deferasirox on the Immune Function of Patients With Hematologic Diseases and Transfusion-Related Iron Overload Completed NCT01273766 Phase 2 deferasirox
12 Phase II Study of MK-2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2 Akt inhibitor MK2206
13 Phase II Study of Arsenic Trioxide (NSC #706363) in Relapsed and Refractory Intermediate and High-Grade Non-Hodgkin's Lymphoma Completed NCT00005040 Phase 2 arsenic trioxide
14 A Phase II Study of G3139 (Bcl-2 Antisense) And Rituximab in Patients With Recurrent B-cell Non-Hodgkinâs Lymphomas Completed NCT00054639 Phase 2
15 Pilot Study of Prophylactic Dose-Escalation Donor Lymphocyte Infusion After T Cell Depleted Allogeneic Stem Cell Transplant in High Risk Patients With Hematologic Malignancies Completed NCT01839916 Phase 2
16 Addition of Pre- and Post-Transplant Rituximab for Patients Undergoing Non-myeloablative Allogeneic Hematopoietic Cell Transplantation With Relapsed or Refractory CD20+ B-Cell Malignancies Completed NCT00867529 Phase 2
17 A Phase II Study of Sirolimus, Tacrolimus and Thymoglobulin, as Graft-versus-Host Prophylaxis in Patients Undergoing Unrelated Donor Hematopoietic Cell Transplantation Completed NCT00589563 Phase 2 cyclophosphamide;etoposide;fludarabine phosphate;melphalan;methotrexate;sirolimus;tacrolimus
18 A Phase II Study of Bendamustine (B), Etoposide (E), Dexamethasone (D), and GCSF for Peripheral Blood Hematopoietic Stem Cell Mobilization (BED) Completed NCT01110135 Phase 2 bendamustine hydrochloride;dexamethasone;etoposide
19 Gem-CHOP: A Randomized Phase II Study of Gemcitabine Combined With CHOP in Untreated Aggressive Non-Hodgkin's Lymphoma Completed NCT00079261 Phase 2 CHOP regimen;cyclophosphamide;doxorubicin hydrochloride;gemcitabine hydrochloride;prednisone;vincristine sulfate
20 A Phase II Clinical Trial of 17-(Allylamino)-17- Demethoxygeldanamycin (17-AAG, NSC 330507 and EPL Diluent, NSC 704057) in Adults With Systemic Mastocytosis Completed NCT00132015 Phase 2 tanespimycin
21 A Phase II Study Evaluating the Efficacy of Gemcitabine, Carboplatin, and Dexamethasone and Rituximab for Previously Treated Lymphoid Malignancies Completed NCT00072514 Phase 2 gemcitabine hydrochloride;carboplatin;dexamethasone
22 A Pilot Trial of Vorinostat Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease Following Unrelated Donor Hematopoietic Stem Cell Transplantation Completed NCT01789255 Phase 2 vorinostat;tacrolimus;cyclosporine;methotrexate
23 A Phase II Study to Evaluate the Efficacy of Oral Beclomethasone Dipropionate for Prevention of Acute GVHD After Hematopoietic Cell Transplantation With Myeloablative Conditioning Regimens Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
24 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
25 Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia Completed NCT00612716 Phase 2 busulfan;cyclophosphamide
26 A Pilot Study Investigating the Effects of Glutamine and Vincristine-Induced Neuropathy in Pediatric Patients With Cancer Completed NCT00365768 Phase 2 Glutamine
27 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
28 High-dose Busulfan, High-dose Cyclophosphamide, and Allogeneic Bone Marrow Transplantation for Leukemia, Myelodysplastic Syndromes, Multiple Myeloma and Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
29 A Multi-Center Study of Nonmyeloablative Conditioning With TBI or Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies With Post Grafting Immunosuppression With Tacrolimus and Mycophenolate Mofetil Completed NCT00089011 Phase 2 fludarabine phosphate;mycophenolate mofetil;tacrolimus
30 Prolonged Mycophenolate Mofetil and Truncated Cyclosporine Postgrafting Immunosuppression to Reduce Life-Threatening GVHD After Unrelated Donor Peripheral Blood Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies and Renal Cell Carcinoma - A Multi-Center Trial Completed NCT00078858 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
31 Induction of Mixed Hematopoietic Chimerism in Patients Using Fludarabine, Low Dose TBI, PBSC Infusion and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil Completed NCT00006251 Phase 1, Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
32 A Phase II Trial Evaluating the Safety and Efficacy of Non-myeloablative 90Y-Ibritumomab Tiuxetan (Anti-CD20) Antibody With Fludarabine, Low-Dose Total Body Irradiation (TBI) and HLA Matched Allogeneic Transplantation for Relapsed B-cell Lymphoma Completed NCT00119392 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
33 Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
34 Campath® [Alemtuzumab] Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class I Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies - A Multi-Center Trial Completed NCT00040846 Phase 2 fludarabine phosphate;mycophenolate mofetil;cyclosporine
35 Nonmyeloablative Hematopoietic Stem Cell Transplantation for Patients With High-Risk Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Phase II Trial of Combined Immunosuppression Before and After Transplantation Completed NCT00049504 Phase 2 cyclophosphamide;fludarabine phosphate;tacrolimus;mycophenolate mofetil
36 A Phase 1b/2a Study of ABT-888 in Combination With Bendamustine +/- Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors Completed NCT01326702 Phase 1, Phase 2 Bendamustine Hydrochloride;Veliparib
37 A Phase I/II Study of Vorinostat Plus Rituximab, Ifosphamide, Carboplatin, and Etoposide for Patients With Relapsed or Refractory Lymphoid Malignancies or Untreated T- or Mantle Cell Lymphoma Completed NCT00601718 Phase 1, Phase 2 vorinostat;ifosfamide;carboplatin;etoposide
38 A Phase II Trial of Reduced Intensity Allogeneic Stem Cell Transplantation With Fludarabine, Melphalan and Low Dose Total Body Irradiation Completed NCT01529827 Phase 2 fludarabine phosphate;melphalan;tacrolimus;mycophenolate mofetil;methotrexate
39 A Phase II Study to Evaluate the Efficacy of Posttransplant Cyclophosphamide for Prevention of Chronic Graft-versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation Completed NCT01427881 Phase 2 cyclophosphamide;cyclosporine;fludarabine phosphate;busulfan
40 A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma Completed NCT00474929 Phase 1, Phase 2 RAD001;Sorafenib
41 RC05CB A Pilot, Randomized Comparison of Standard Weekly Epoetin Alfa to Every-3-Week-Epoetin Alfa and Every 3-Week Darbepoetin Alfa Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
42 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
43 A Phase I Evaluation of the Combination of Pegylated Liposomal Doxorubicin (Doxil®) With PS-341 in Patients With Refractory Hematologic and Solid Malignancies Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
44 A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma Completed NCT00238433 Phase 2 busulfan;melphalan;thiotepa
45 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Undergoing Dose-Adjusted Treatment With A Maximally Intensive Busulfex-Based Therapeutic Regimen Completed NCT00448357 Phase 1, Phase 2 busulfan;fludarabine phosphate;tacrolimus;methotrexate
46 Allogeneic Hematopoietic Cell Transplantation for Patients With Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment With a More Intensive Therapeutic Regimen Completed NCT00448201 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
47 Pre-administration of Rabbit Antithymocyte Globulin to Optimize Donor T-Cell Engraftment Following Reduced Intensity Allogeneic Peripheral Blood Progenitor Cell Transplantation From Matched-Related Donors Completed NCT00787761 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;methotrexate;tacrolimus
48 Treatment and Natural History Study of Lymphomatoid Granulomatosis Recruiting NCT00001379 Phase 2 Rituxan and EPOCH
49 Prospective, Multi-center Phase I/II Trial of Lenalidomide and Dose-Adjusted EPOCH-R in MYC-Associated B-Cell Lymphomas Recruiting NCT02213913 Phase 1, Phase 2 lenalidomide;etoposide;prednisone;vincristine sulfate;doxorubicin hydrochloride;cyclophosphamide
50 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab

Search NIH Clinical Center for Lymphomatoid Granulomatosis

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Interferon Alfa-2b

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Lymphomatoid Granulomatosis cell therapies at LifeMap Discovery.

Genetic Tests for Lymphomatoid Granulomatosis

Anatomical Context for Lymphomatoid Granulomatosis

MalaCards organs/tissues related to Lymphomatoid Granulomatosis:

40
B Cells, Lung, T Cells, Skin, Liver, Kidney, Bone

Publications for Lymphomatoid Granulomatosis

Articles related to Lymphomatoid Granulomatosis:

(show top 50) (show all 722)
# Title Authors PMID Year
1
The role of Mig, the monokine induced by interferon-gamma, and IP-10, the interferon-gamma-inducible protein-10, in tissue necrosis and vascular damage associated with Epstein-Barr virus-positive lymphoproliferative disease. 54 61
9354680 1997
2
[Lymphomatoid granulomatosis--remission induction with interferon-alpha 2b]. 54 61
9340250 1997
3
Association of lymphomatoid granulomatosis with Epstein-Barr viral infection of B lymphocytes and response to interferon-alpha 2b. 54 61
8639820 1996
4
Extranodal NK/T cell lymphoma and lymphomatoid granulomatosis in a patient with chronic lymphocytic leukaemia: Case report for a new perspective on Richter syndrome. 61
32384485 2020
5
Pulmonary Recurrence of Lymphomatoid Granulomatosis Diagnosed on F-18 FDG PET/CT. 61
32351275 2020
6
Pathobiology and treatment of lymphomatoid granulomatosis, a rare EBV-driven disorder. 61
32107539 2020
7
[A Case of Primary Central Nervous System Lymphomatoid Granulomatosis that was Completely Ameliorated by Corticosteroid Treatment]. 61
32036342 2020
8
Diffuse large B-cell lymphoma variants: an update. 61
31735345 2020
9
Pulmonary Lymphomatoid Granulomatosis With Hemophagocytic Lymphohistiocytosis as the Initial Manifestation. 61
32064234 2020
10
Isolated lymphomatoid granulomatosis of the central nervous system: A case report and literature review. 61
31746046 2019
11
Simultaneous Presentation of Lymphomatoid Granulomatosis and Multiple myeloma in an Immunodeficient Patient with Rheumatoid Arthritis. 61
31243219 2019
12
An atypical case of a pulmonary mass in an immunocompromised patient. 61
31423951 2019
13
An update on IgG4-related lung disease. 61
31227290 2019
14
A rare lymphoproliferative disorder associated with immunomodulating therapy in Crohn's disease. 61
31021160 2019
15
Oral Manifestation of Lymphomatoid Granulomatosis. 61
29542064 2019
16
A Case of Methotrexate-Associated Lymphoproliferative Disorder (Lymphomatoid Granulomatosis) of the Skin. 61
31112139 2019
17
Lymphomatoid granulomatosis mimicking cancer and sarcoidosis. 61
30288554 2019
18
Oral ulceration: an unusual manifestation of lymphomatoid granulomatosis. 61
30284019 2019
19
Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. 61
30828876 2019
20
Lymphomatoid granulomatosis: a rare lymphoproliferative disease in the pediatric age. 61
30337062 2019
21
Cutaneous lymphomatoid granulomatosis with long-term absence of lung involvement. 61
30010204 2019
22
Coincidence of lymphomatoid granulomatosis, chronic myelomonocytic leukemia, and anaplastic T cell lymphoma after methotrexate therapy for rheumatoid arthritis. 61
29982850 2019
23
The Role and Pitfall of F18-FDG PET/CT in Surveillance of High Grade Pulmonary Lymphomatoid Granulomatosis. 61
30826140 2019
24
Lymphomatoid Granulomatosis in a Patient with Chronic Lymphocytic Leukemia and Rapidly Progressing Peribronchovascular Pulmonary Infiltrates. 61
30805241 2019
25
Magnesium Restores Activity to Peripheral Blood Cells in a Patient With Functionally Impaired Interleukin-2-Inducible T Cell Kinase. 61
31507602 2019
26
Pitfall of 18F-FDG PET/CT in Characterization of Relapsed Multisystem Lymphomatoid Granulomatosis. 61
29884684 2018
27
Pediatric oral Epstein-Barr virus associated self-remitting CD30+ lymphoproliferative disorder: A distinct entity. 61
30292067 2018
28
Case 259: Primary Central Nervous System Lymphomatoid Granulomatosis Mimicking Chronic Lymphocytic Inflammation with Pontine Perivascular Enhancement Responsive to Steroids (CLIPPERS). 61
30332362 2018
29
The Spontaneous Regression of Grade 3 Methotrexate-related Lymphomatoid Granulomatosis: A Case Report and Literature Review. 61
29877270 2018
30
Lymphomatoid granulomatosis and large granular lymphocyte leukemia, a rare association of two lymphoproliferative disorders. 61
29473430 2018
31
Lymphomatoid Granulomatosis with Isolated Cutaneous Lesions: Prolonged Remission After DA-EPOCH Protocol 61
29856361 2018
32
Cartilage hair hypoplasia with cutaneous lymphomatoid granulomatosis. 61
29744913 2018
33
Primary pulmonary lymphoproliferative neoplasms. 61
29697079 2018
34
Angiocentric lymph proliferative disorder (lymphomatoid granulomatosis) in a person with newly-diagnosed HIV infection: a case report. 61
29739366 2018
35
Lymphomatoid granulomatosis: A case series from South India. 61
29676363 2018
36
Primary lymphomatoid granulomatosis in the central nervous system: A report of three cases. 61
29635846 2018
37
EBV-Positive Lymphoproliferations of B- T- and NK-Cell Derivation in Non-Immunocompromised Hosts. 61
29518976 2018
38
Lymphomatoid Granulomatosis in a 14-Year-Old Boy with Trisomy 21 and History of B-Lymphoblastic Leukemia/Lymphoma. 61
29336635 2018
39
Lymphomatoid Granulomatosis: A Rare Tumor with Poor Prognosis. 61
28838746 2018
40
Pulmonary lymphomatoid granulomatosis diagnosed by image-guided core needle biopsy. 61
29020803 2018
41
Unique case of trigeminal neuralgia due to Epstein-Barr-virus-associated B-cell lymphomatoid granulomatosis of the Meckel's cave and cavernous sinus: Important clinical and therapeutic implications. 61
30105142 2018
42
Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder. 61
29112013 2018
43
A Case of Hodgkin Lymphoma Mimicking Lymphomatoid Granulomatosis Diagnosed at Autopsy. 61
29165611 2017
44
Epstein-Barr virus-positive diffuse large B-cell lymphoma. 61
28966459 2017
45
Unsuspected lymphomatoid granulomatosis in a patient with antisynthetase syndrome. 61
29136066 2017
46
Rare case of pulmonary lymphomatoid granulomatosis in conjunction with tuberculosis: A case report. 61
29049243 2017
47
The Complete Remission of Acquired Immunodeficiency Syndrome-associated Isolated Central Nervous System Lymphomatoid Granulomatosis: A Case Report and Review of the Literature. 61
28824078 2017
48
Epstein-Barr Virus-associated Lymphoproliferative Disorders in the Skin. 61
28477890 2017
49
Cutaneous human immunodeficiency virus (HIV)-associated lymphomatoid granulomatosis: complete regression following antiretroviral therapy. 61
28188620 2017
50
Lymphomatoid granulomatosis initially presenting as ulcerated subcutaneous and muscle lesions without pulmonary involvement. 61
27988929 2017

Variations for Lymphomatoid Granulomatosis

Expression for Lymphomatoid Granulomatosis

Search GEO for disease gene expression data for Lymphomatoid Granulomatosis.

Pathways for Lymphomatoid Granulomatosis

Pathways related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.43 IFNA2 IFNA1 CXCL9
2
Show member pathways
11.67 IFNA2 IFNA1 GZMB CXCL9
3
Show member pathways
11.61 IFNA2 IFNA1 GZMB
4 11.28 IFNA2 IFNA1
5 10.93 IFNA2 IFNA1
6 10.72 IFNA2 CXCL9

GO Terms for Lymphomatoid Granulomatosis

Biological processes related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 apoptotic process GO:0006915 9.69 TIA1 IFNA2 GZMB
2 negative regulation of translation GO:0017148 9.49 TIA1 GZMB
3 B cell differentiation GO:0030183 9.48 IFNA2 IFNA1
4 type I interferon signaling pathway GO:0060337 9.46 IFNA2 IFNA1
5 humoral immune response GO:0006959 9.43 IFNA2 IFNA1
6 B cell proliferation GO:0042100 9.4 IFNA2 IFNA1
7 response to exogenous dsRNA GO:0043330 9.37 IFNA2 IFNA1
8 T cell activation involved in immune response GO:0002286 9.32 IFNA2 IFNA1
9 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.26 IFNA2 IFNA1
10 natural killer cell activation involved in immune response GO:0002323 9.16 IFNA2 IFNA1
11 defense response to virus GO:0051607 9.13 IFNA2 IFNA1 CXCL9
12 defense response GO:0006952 8.8 IFNA2 IFNA1 CXCL9

Molecular functions related to Lymphomatoid Granulomatosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.16 IFNA2 IFNA1
2 cytokine activity GO:0005125 9.13 IFNA2 IFNA1 CXCL9
3 type I interferon receptor binding GO:0005132 8.62 IFNA2 IFNA1

Sources for Lymphomatoid Granulomatosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....